PTPRD and melanoma: As TET1 and PTPRD mutations were the only significant predictors of outcomes in the melanoma discovery cohort, we next explored their prognostic utility in a valuation cohort consisting of melanoma patients from three independent immunogenomic studies all receiving ICIs (N = 212).